JP2024045121A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024045121A5 JP2024045121A5 JP2023218600A JP2023218600A JP2024045121A5 JP 2024045121 A5 JP2024045121 A5 JP 2024045121A5 JP 2023218600 A JP2023218600 A JP 2023218600A JP 2023218600 A JP2023218600 A JP 2023218600A JP 2024045121 A5 JP2024045121 A5 JP 2024045121A5
- Authority
- JP
- Japan
- Prior art keywords
- administered subcutaneously
- formulation
- isolated antibody
- use according
- milligrams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 208000023275 Autoimmune disease Diseases 0.000 claims 6
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 4
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 4
- 206010021263 IgA nephropathy Diseases 0.000 claims 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 3
- 210000003743 erythrocyte Anatomy 0.000 claims 3
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649489P | 2018-03-28 | 2018-03-28 | |
| US62/649,489 | 2018-03-28 | ||
| PCT/IB2019/000314 WO2019186273A1 (en) | 2018-03-28 | 2019-03-27 | Subcutaneous dosing of anti-cd38 antibodies |
| JP2020551797A JP7526099B2 (ja) | 2018-03-28 | 2019-03-27 | 抗ｃｄ３８抗体の皮下投薬 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551797A Division JP7526099B2 (ja) | 2018-03-28 | 2019-03-27 | 抗ｃｄ３８抗体の皮下投薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024045121A JP2024045121A (ja) | 2024-04-02 |
| JP2024045121A5 true JP2024045121A5 (cg-RX-API-DMAC7.html) | 2024-11-15 |
Family
ID=66647425
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551797A Active JP7526099B2 (ja) | 2018-03-28 | 2019-03-27 | 抗ｃｄ３８抗体の皮下投薬 |
| JP2023218600A Pending JP2024045121A (ja) | 2018-03-28 | 2023-12-25 | 抗ｃｄ３８抗体の皮下投薬 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551797A Active JP7526099B2 (ja) | 2018-03-28 | 2019-03-27 | 抗ｃｄ３８抗体の皮下投薬 |
Country Status (12)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
| BR112017024877A2 (pt) | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| ES2912729T3 (es) | 2015-11-03 | 2022-05-27 | Janssen Biotech Inc | Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| CN112513087B (zh) * | 2018-09-11 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 抗cd38抗体、其抗原结合片段及医药用途 |
| CA3116878A1 (en) * | 2018-10-17 | 2020-04-23 | Janssen Biotech, Inc. | Method of providing subcutaneous administration of anti-cd38 antibodies |
| EP4069743A1 (en) * | 2019-12-05 | 2022-10-12 | Sanofi-Aventis U.S. LLC | Formulations of anti-cd38 antibodies for subcutaneous administration |
| MX2022014297A (es) * | 2020-05-15 | 2023-02-09 | Takeda Pharmaceuticals Co | Administración del inhibidor de la enzima activadora (sae) del modificador similar a la ubiquitina pequeña (sumo) y anticuerpos anti cúmulo de diferenciación 38 (cd38). |
| EP4376869A1 (en) | 2021-07-28 | 2024-06-05 | Genentech, Inc. | Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers |
| AU2022350815A1 (en) * | 2021-09-23 | 2024-05-02 | Sound Biopharmaceuticals Co. Ltd. | Cd38 monoclonal antibody and application thereof |
| AU2023412139A1 (en) * | 2022-12-21 | 2025-06-19 | Sound Biopharmaceuticals Co. Ltd. | Cd38 monoclonal antibody and use thereof |
| WO2024147934A1 (en) | 2023-01-06 | 2024-07-11 | Takeda Pharmaceutical Company Limited | Anti-cd38 antibodies for the treatment of autoimmune diseases |
| WO2025193746A1 (en) | 2024-03-12 | 2025-09-18 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia |
| WO2025235919A1 (en) | 2024-05-09 | 2025-11-13 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| IT1320715B1 (it) | 2000-10-19 | 2003-12-10 | Cselt Centro Studi Lab Telecom | Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7497862B2 (en) | 2001-08-03 | 2009-03-03 | Tyco Healthcare Group Lp | Tissue marking apparatus and method |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| CA2602375C (en) * | 2005-03-23 | 2018-07-24 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| EP2799451A1 (en) | 2005-05-24 | 2014-11-05 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 |
| EP1931709B1 (en) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| MX373301B (es) * | 2013-10-31 | 2020-04-24 | Sanofi Sa | Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos. |
| HRP20210552T1 (hr) * | 2015-05-13 | 2021-05-14 | Morphosys Ag | Liječenje multiplog mijeloma (mm) |
| ES2912729T3 (es) * | 2015-11-03 | 2022-05-27 | Janssen Biotech Inc | Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos |
| JP7316930B2 (ja) * | 2016-07-15 | 2023-07-28 | 武田薬品工業株式会社 | 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料 |
-
2019
- 2019-03-27 JP JP2020551797A patent/JP7526099B2/ja active Active
- 2019-03-27 WO PCT/IB2019/000314 patent/WO2019186273A1/en not_active Ceased
- 2019-03-27 EP EP19726474.0A patent/EP3774915A1/en active Pending
- 2019-03-27 KR KR1020207030604A patent/KR20210002499A/ko not_active Ceased
- 2019-03-27 KR KR1020257024758A patent/KR20250117714A/ko active Pending
- 2019-03-27 BR BR112020019710-6A patent/BR112020019710A2/pt unknown
- 2019-03-27 CA CA3095086A patent/CA3095086A1/en active Pending
- 2019-03-27 US US17/041,783 patent/US20210047427A1/en active Pending
- 2019-03-27 AU AU2019244478A patent/AU2019244478B2/en active Active
- 2019-03-27 MX MX2020010144A patent/MX2020010144A/es unknown
- 2019-03-27 CN CN201980032101.8A patent/CN112154156A/zh active Pending
- 2019-03-28 TW TW113121338A patent/TW202504926A/zh unknown
- 2019-03-28 TW TW108110990A patent/TWI847979B/zh active
-
2020
- 2020-10-22 CO CONC2020/0013252A patent/CO2020013252A2/es unknown
-
2023
- 2023-12-25 JP JP2023218600A patent/JP2024045121A/ja active Pending
-
2025
- 2025-10-29 AU AU2025259859A patent/AU2025259859A1/en active Pending